James Abell
← Back to Team

James Abell

Senior Advisor


James retired in 2019 after more than 20 years as Abingworth’s CFO responsible for finance, compliance and administration as well as investment matters, focusing on start-up companies. His directorships have included Avillion, SFJ Pharmaceuticals, Chroma Therapeutics, Clinical Designs and Syntaxin. James has been retained as a Senior Adviser concentrating on clinical co-development deals.

Previously James was CFO of Prolifix, a start-up biotech company. He trained and qualified as a Chartered Accountant with KPMG and holds a degree in Biology with Chemistry from the University of Southampton.